Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Bladder Cancer

Free Subscription 10.11.2025 1 ACS Omega 1 Actas Urol Esp (Engl Ed) 1 Am Soc Clin Oncol Educ Book 1 Ann Med Surg (Lond) 2 Ann Surg Oncol 1 Anticancer Drugs 1 Biom J 1 BJU Int 2 BMC Cancer 1 BMC Urol 1 CA Cancer J Clin 1 Cancer Imaging 1 Cell Cycle 1 Cureus 1 Curr Opin Urol 1 Discov Oncol 4 Eur Urol 2 Expert Rev Anticancer Ther 1 Expert Rev Mol Diagn 1 Front Biosci (Landmark Ed) 1 Front Immunol 1 Front Oncol 1 Int J Genomics 1 Int J Surg 2 Int J Urol 3 Investig Clin Urol 1 Isr Med Assoc J 1 J Clin Oncol 1 J Endourol 1 J Proteomics 2 J Transl Med 2 J Urol 1 NAR Cancer 1 Nat Rev Urol 1 Oncol Lett 1 Oncol Ther 1 Pharmacol Res 1 Phytomedicine 1 Research (Wash D C) 2 Sci Rep 1 Toxicol Res (Camb) 4 Urologia 2 World J Urol 1 Zhonghua Bing Li Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Omega

1. SUN Y, Ding M, Sun J, Zhang Q, et al
   Novel Biomarkers for Lymph Node Metastasis and Prognosis of Bladder Cancer by Bioinformatics Analysis.
   ACS Omega. 2025;10:50124-50138.
   PubMed         Abstract available
   
   

   
   Actas Urol Esp (Engl Ed)

2. FARRE A, Huguet J, Basile G, Dieguez L, et al
   Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy.
   Actas Urol Esp (Engl Ed). 2025;49:501834.
   PubMed         Abstract available
   
   

   
   Am Soc Clin Oncol Educ Book

3. FILON M, Schmidt B
   Erratum: New Treatment Options for Non-Muscle-Invasive Bladder Cancer.
   Am Soc Clin Oncol Educ Book. 2025;45:e471942CX1.
   PubMed        
   
   

   
   Ann Med Surg (Lond)

4. ALI HS, Bilal E, Noor H, Khalid M, et al
   Critical appraisal of "A cross-sectional study on the effects of intravesical BCG on urinary microbiota in bladder cancer patients".
   Ann Med Surg (Lond). 2025;87:7786-7787.
   PubMed        
   
   

   
   Ann Surg Oncol

5. MARMIROLI A, Longoni M, Le QC, Falkenbach F, et al
   Adverse In-hospital Outcomes According to Pelvic Lymph Node Dissection at Partial Cystectomy.
   Ann Surg Oncol. 2025;32:10279-10284.
   PubMed         Abstract available
   
   
6. POLVERINO F, Marmiroli A, Longoni M, Le QC, et al
   The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes After Radical Cystectomy and Ileal Conduit Urinary Diversion.
   Ann Surg Oncol. 2025;32:10328-10334.
   PubMed         Abstract available
   
   

   
   Anticancer Drugs

7. YANG G, Zhu X, Wei W, Yin X, et al
   Unlocking the role of prostate transmembrane androgen inducible protein 1 in gemcitabine resistance: modulation of P38-mitogen-activated protein kinase/C-C motif chemokine ligand 2 and M2 macrophage polarization in bladder cancer.
   Anticancer Drugs. 2025 Oct 16. doi: 10.1097/CAD.0000000000001769.
   PubMed         Abstract available
   
   

   
   Biom J

8. LEDESMA L, Pullenayegum E
   Intercept Estimation of Semi-Parametric Joint Models in the Context of Longitudinal Data Subject to Irregular Observations.
   Biom J. 2025;67:e70088.
   PubMed         Abstract available
   
   

   
   BJU Int

9. RHODES AC, McClintic KA, Witt E, Nwosu I, et al
   Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
   BJU Int. 2025 Nov 3. doi: 10.1111/bju.70060.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. ZHAO Y, Ji Z, Sun W, Liu X, et al
    Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:1702.
    PubMed         Abstract available
    
    
11. HU D, Liu H, Li M, Wu W, et al
    Prognostic value of prostate volume and nomograms for predicting recurrence in patients with non-muscle invasive bladder cancer: a multi-institutional study.
    BMC Cancer. 2025;25:1719.
    PubMed         Abstract available
    
    

    
    BMC Urol

12. ZHOU T, Liu H, Shen Y, Shao S, et al
    Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma.
    BMC Urol. 2025;25:276.
    PubMed         Abstract available
    
    

    
    CA Cancer J Clin

13. YIP W, Jaime-Casas S, Kothari A, Sullivan M, et al
    Urothelial carcinoma: Perioperative considerations from top to bottom.
    CA Cancer J Clin. 2025;75:528-551.
    PubMed         Abstract available
    
    

    
    Cancer Imaging

14. GUO J, Fan Z, Li D, Chen Q, et al
    Parameter-driven habitat imaging based on intravoxel incoherent motion MRI for preoperative prediction of muscle invasion in bladder cancer.
    Cancer Imaging. 2025;25:125.
    PubMed         Abstract available
    
    

    
    Cell Cycle

15. YANG T, Kong SP, Xu QL, Zhan CX, et al
    CKS2 promotes the malignant phenotypes of bladder cancer cells via PI3K/AKT signaling pathway activation.
    Cell Cycle. 2025 Nov 7:1-15. doi: 10.1080/15384101.2025.2586117.
    PubMed         Abstract available
    
    

    
    Cureus

16. ENEMOH O, Adefehinti M, Sanni QA, Ogunbadejo HA, et al
    Exploring the Need for a Consensus Guideline for the Management of Non-Muscle-Invasive Bladder Cancer: A Scoping Review.
    Cureus. 2025;17:e93553.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

17. ROESSLER N, Miszczyk M, Berger W, Englinger B, et al
    Nectin-4 in bladder cancer: biology and predictive biomarker potential.
    Curr Opin Urol. 2025 Oct 23. doi: 10.1097/MOU.0000000000001354.
    PubMed         Abstract available
    
    

    
    Discov Oncol

18. XU Y, Wang X, Wang X, Li K, et al
    Integrating single-cell transcriptomics and machine learning reveals 4-aminobiphenyl exposure signatures and novel diagnostic biomarkers in bladder cancer.
    Discov Oncol. 2025;16:2023.
    PubMed         Abstract available
    
    

    
    Eur Urol

19. PANEBIANCO V, Briganti A, Efstathiou JA, Galgano SJ, et al
    Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04769-4. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
20. MORTEZAVI A
    Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04777-3. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
21. HUSSAIN SA, Catto JWF
    Non-muscle-invasive Bladder Cancer: Many New Options, If You Can Afford Them.
    Eur Urol. 2025 Nov 1:S0302-2838(25)04771-2. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
22. HUANG H, Ma W, Zeng X, Liu B, et al
    Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.
    Eur Urol. 2025 Nov 4:S0302-2838(25)04768-2. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

23. MALSHY K, Steinmetz A, Messing EM
    Implementation challenges of single-instillation intravesical chemotherapy following transurethral resection of bladder tumor.
    Expert Rev Anticancer Ther. 2025;25:1227-1234.
    PubMed         Abstract available
    
    
24. MEMBRIBES SC, Nally E, Jackson-Spence F, Graham C, et al
    Established and emerging biomarkers approaches in urothelial carcinoma.
    Expert Rev Anticancer Ther. 2025;25:1235-1241.
    PubMed         Abstract available
    
    

    
    Expert Rev Mol Diagn

25. INOUE S, Miszczyk M, Suleja A, Matsukawa A, et al
    Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook.
    Expert Rev Mol Diagn. 2025;25:793-799.
    PubMed         Abstract available
    
    

    
    Front Biosci (Landmark Ed)

26. TANG Z, Peng J, Pan X, Kong Y, et al
    An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer.
    Front Biosci (Landmark Ed). 2025;30:45386.
    PubMed         Abstract available
    
    

    
    Front Immunol

27. WANG L, Yang J, Xu Z, Tao B, et al
    Comprehensive analysis of single-cell and bulk transcriptomes reveals key B-cell genes and immune microenvironment regulation in bladder cancer.
    Front Immunol. 2025;16:1600254.
    PubMed         Abstract available
    
    

    
    Front Oncol

28. ZHANG D, Chen B, Ye J, Bai Y, et al
    Integrated assessment of non-invasive diagnostic tools for bladder cancer: a network meta-analysis.
    Front Oncol. 2025;15:1649420.
    PubMed         Abstract available
    
    

    
    Int J Genomics

29. PENG Z, Yang J, Jia R, Wu T, et al
    Sphingolipid Metabolism Dysregulation Drives Immune Microenvironment Remodeling and Predicts Prognosis in Bladder Cancer.
    Int J Genomics. 2025;2025:6085216.
    PubMed         Abstract available
    
    

    
    Int J Surg

30. REN JW, Ye JJ, Bai YJ, Han P, et al
    The prognostic value of circadian syndrome in non-muscle-invasive bladder cancer: a retrospective cohort study.
    Int J Surg. 2025 Nov 4. doi: 10.1097/JS9.0000000000003740.
    PubMed         Abstract available
    
    

    
    Int J Urol

31. MATSUDA K, Tsutsumi M, Kanazawa T, Chihara I, et al
    Limited Response to Enfortumab Vedotin-Pembrolizumab in Three Consecutive Cases of Neoadjuvant Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025;32:1712-1714.
    PubMed        
    
    
32. SALAH S, Ito K, Kita Y, Kobayashi T, et al
    Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model.
    Int J Urol. 2025;32:1569-1575.
    PubMed         Abstract available
    
    

    
    Investig Clin Urol

33. LEE H, So SW, Han JH, Yuk HD, et al
    The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer.
    Investig Clin Urol. 2025;66:509-515.
    PubMed         Abstract available
    
    
34. RAMASAMY RP, Chai CA, Cormio A, Rajandram R, et al
    Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review.
    Investig Clin Urol. 2025;66:482-490.
    PubMed         Abstract available
    
    
35. KIM KH, Phan DTT, Ha HK, Jung EH, et al
    Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives.
    Investig Clin Urol. 2025;66:471-481.
    PubMed         Abstract available
    
    

    
    Isr Med Assoc J

36. TAYLOR N, Heering G, Icht O, Kozlova D, et al
    Changing Trends in Bladder Cancer Epidemiology in the Israeli Population: 1996-2016.
    Isr Med Assoc J. 2025;27:684-690.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

37. BIAN X, Yang T, Yin H, Hu B, et al
    Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.
    J Clin Oncol. 2025;43:3505-3515.
    PubMed         Abstract available
    
    

    
    J Endourol

38. PORRECA A, Marino F, Marchi D, Giampaoli M, et al
    The Role of Holmium Laser Enucleation of the Prostate in Reducing the Risk of Bladder Cancer Recurrence and Progression.
    J Endourol. 2025 Nov 5. doi: 10.1177/08927790251390869.
    PubMed         Abstract available
    
    

    
    J Proteomics

39. FENG Z, Zhang B, Liu Y, Yang F, et al
    Decoding bladder cancer aggressiveness: A proteomic, phosphoproteomic and metabolomic approach.
    J Proteomics. 2025;323:105553.
    PubMed         Abstract available
    
    

    
    J Transl Med

40. ZHANG H, Huang W, Cai Z, Mou S, et al
    Correction: CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.
    J Transl Med. 2025;23:1225.
    PubMed        
    
    
41. YOU C, Fang Q, Qing L, Xiao X, et al
    JUN-ENPP1-cGAS-STING axis mediates immune evasion and tumor progression in bladder cancer.
    J Transl Med. 2025;23:1222.
    PubMed         Abstract available
    
    

    
    J Urol

42. STOVER AM, Mueller D, Carda-Auten J, Hilton A, et al
    Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial: Erratum.
    J Urol. 2025;214:674.
    PubMed        
    
    
43. DONAT SM, Tin AL, Vickers AJ, Herr H, et al
    Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder.
    J Urol. 2025;214:591-600.
    PubMed         Abstract available
    
    

    
    NAR Cancer

44. GAMMELL F, Li J, Elco C, Plavicki J, et al
    THRESHOLD: a comprehensive transcriptomic analysis tool for evaluating gene saturation and impact in disease progression.
    NAR Cancer. 2025;7:zcaf032.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

45. MASONE MC
    Mitochondrial metabolic alterations fuel bladder cancer initiation.
    Nat Rev Urol. 2025 Nov 4. doi: 10.1038/s41585-025-01110.
    PubMed        
    
    

    
    Oncol Lett

46. HAO L, Zhao Y, Li ZG, He HG, et al
    [Retracted] Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells.
    Oncol Lett. 2025;31:1.
    PubMed         Abstract available
    
    

    
    Oncol Ther

47. STERNBERG CN, Squires P, Song Y, Wu A, et al
    Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis.
    Oncol Ther. 2025 Nov 4. doi: 10.1007/s40487-025-00399.
    PubMed         Abstract available
    
    

    
    Pharmacol Res

48. SONG Y, Jiang S, Peng Y, Du Y, et al
    FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma.
    Pharmacol Res. 2025;221:107968.
    PubMed         Abstract available
    
    

    
    Phytomedicine

49. ZHAI J, Tan R, Yuan S, Che B, et al
    Unveiling tectorigenin: A novel ferroptosis inducer targeting EGFR in bladder cancer.
    Phytomedicine. 2025;148:157419.
    PubMed         Abstract available
    
    

    
    Research (Wash D C)

50. SUN J, Shi Y, Yu K, Huang S, et al
    Hypoxia-Induced Histone Lactylation Drives Cisplatin Resistance in Bladder Cancer by Promoting RBM15-Dependent m(6)A Methylation of IGFBP3.
    Research (Wash D C). 2025;8:0970.
    PubMed         Abstract available
    
    

    
    Sci Rep

51. LI W, Lv R, Su H, Fan Y, et al
    Clinicopathological significance of Kruppel-like factor 15 and epithelial-to-mesenchymal transition related factors in bladder cancer.
    Sci Rep. 2025;15:38862.
    PubMed         Abstract available
    
    
52. YANG B, Wei Y, Liu S, Wang J, et al
    Integration of Single-cell and bulk RNA sequencing data uncovers lymphatic metastasis-related prognostic genes and a predictive model in bladder cancer.
    Sci Rep. 2025;15:38973.
    PubMed         Abstract available
    
    

    
    Toxicol Res (Camb)

53. WANG Y, Li C
    A network toxicology approach to elucidate shared oncogenic pathways of Aristolochic acids in prostate, kidney, and bladder cancers.
    Toxicol Res (Camb). 2025;14:tfaf150.
    PubMed         Abstract available
    
    

    
    Urologia

54. XU X, Ding Y, Guo X, Cao J, et al
    Global hotspots and trends in robotics of bladder cancer: A bibliometric and visualized analysis.
    Urologia. 2025 Nov 4:3915603251388758. doi: 10.1177/03915603251388758.
    PubMed         Abstract available
    
    
55. AKHTAR SN, Gudbrandsdottir G, Aarsaether E, Carlsen B, et al
    Presentation and survival for urachal cancer: Findings from a nationwide multicenter cohort study in Norway.
    Urologia. 2025;92:595-602.
    PubMed         Abstract available
    
    
56. NSAIR A, Malshy K, Hijazi H, Eigner E, et al
    Impact of neoadjuvant chemotherapy on short-term complications following robotic radical cystectomy.
    Urologia. 2025;92:603-610.
    PubMed         Abstract available
    
    
57. GOLOMB D, Atamna F, Leonov Polak M, Avda Y, et al
    Cumulative smoking exposure correlates with progression in high-grade T1 bladder cancer.
    Urologia. 2025 Nov 3:3915603251390744. doi: 10.1177/03915603251390744.
    PubMed         Abstract available
    
    

    
    World J Urol

58. LUNA J, Kampe EOI, Aga-Barfknecht H, Lehne M, et al
    Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data.
    World J Urol. 2025;43:661.
    PubMed         Abstract available
    
    
59. ABOU CHAKRA M, Duquesne I, Mima M, Ohlander S, et al
    Male reproductive and sexual health outcomes following intravesical therapy for non-muscle invasive bladder cancer.
    World J Urol. 2025;43:659.
    PubMed         Abstract available
    
    

    
    Zhonghua Bing Li Xue Za Zhi

60. LI KM, Liu ML, Wu SF, Hong RP, et al
    [Association between HER2 overexpression and recurrence rate in patients with non-muscle-invasive bladder cancer following anthracycline-based intravesical instillation therapy].
    Zhonghua Bing Li Xue Za Zhi. 2025;54:1193-1198.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.